AGP Executive Report
Last update: 10 hours agoClinical CBD/Cannabinoids: Artelo Biosciences dosed the first patient in its Phase 2 DREAM study of ART27.13, an orally delivered, peripherally selective synthetic cannabinoid receptor agonist aimed at lowering eye pressure in glaucoma/ocular hypertension, with initial results expected in Q4 2026. Big Pharma M&A: Jazz Pharmaceuticals agreed to buy Actio Biosciences for $820M upfront (up to $1.3B total) to expand its epilepsy pipeline with ABS-1230, a KCNT1+ precision therapy in Phase 1b/2a. Policy & Regulation: The U.S. Senate voted to delay the federal hemp THC crackdown by about a month (to Dec. 11), while Virginia hemp businesses sued to block new THC limits that could force layoffs and shut down inventory. Public Health: A CDC-linked report says ER diagnoses for cannabis hyperemesis syndrome (“scromiting”) rose 16% from Oct. 2025 to May, alongside a separate study finding frequent cannabis users wake with higher morning cortisol. Local Enforcement: Houston voters will consider a ballot measure to make misdemeanor marijuana possession the “lowest possible” police priority, plus diversion options.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
